This study is testing a treatment for headaches that happen after a subarachnoid hemorrhage (SAH), which is a type of bleeding in the brain. Researchers want to see if adding a "transnasal sphenopalatine ganglion block" to standard pain medication helps reduce headache severity more than medication alone. This block involves using a device called Tx360 to deliver bupivacaine (a numbing medicine) and sometimes dexamethasone (an anti-inflammatory medicine) into your nose to reach a nerve cluster. The study is looking for 40 participants, aged 18 to 100, who have had an acute SAH and can describe their pain. You cannot join if you are pregnant, have an unsecured aneurysm, or cannot verbalize pain. The main goal is to see if this treatment reduces your pain scores. The study status is currently unclear.

Study design

This is a randomized controlled pilot study involving 40 participants. You would be assigned by chance to receive either standard pain medication or standard medication plus the sphenopalatine ganglion block.

What's involved

You would receive the sphenopalatine ganglion block procedure if you are in that group. Your pain scores and opioid use would be monitored from enrollment until ICU discharge, up to 14 days. Individual participation lasts up to four weeks.

Compensation

Not stated in the trial record.

Follow-up

Your pain scores will be measured from enrollment until ICU discharge, up to 14 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.